logo
Vancomycin Pharmacokinetics and Dosing in Premature Neonates
Prediction of Free Levels of Phenytoin and Carbamazepine in Patients Comedicated with Valproic Acid
Inhibition of Trazodone Metabolism by Thioridazine in Humans
Pharmacokinetics of Propofol Infusion in Asian Patients Undergoing Coronary Artery Bypass Grafting
Quality Assurance Program for Cyclosporin G (OG37–325)
Validation of a Quick Modeling Program Generating Clearance Estimates at Steady State for Routine Therapeutic Drug Monitoring
High-Performance Liquid Chromatographic Evaluation of the Effect of Heat Treatment on Trimethoprim and Sulfamethoxazole Stability in Serum
Stability of Tacrolimus (FK 506) and Cyclosporin G in Whole Blood
An Improved Micromethod for Vancomycin Determination by High-Performance Liquid Chromatography
Quantitative Determination of E- and Z-Doxepin and E- and Z-Desmethyldoxepin by High-Performance Liquid Chromatography
Binding of 17-α-Methyltestosterone In Vitro to Human Sex Hormone Binding Globulin and Rat Ventral Prostate Androgen Receptors
Is Routine Measurement of Free Phenytoin Concentrations Rational?
1 ION TRAP MS AND MUMS IN TOXICOLOGICAL ANALYSIS
EXCRETION OF QUININE IN HUMAN SALIVA 2
3 HAIR ANALYSIS OF ANTIEPILEPTIC DRUGS
4 BACLOFEN OVERDOSE OF AGED PATIENTS IN EMERGENCY DEPARTMENT
5 THE CLINICAL SIGNIFICANCE OF REMEDI DRUG PROFILE SYSTEM IN EMERGENCY TOXICOLOGY
6 PERFORMANCE EVALUATION OF THE REMEDi-HS DRUG PROFILING SYSTEM FOR A TOXICOLOGY REFERENCE CENTRE
7 ASSESSMENT OF THE GENOTOXICITY OF 17 NITROHETEROCYCLIC DERIVATIVES BY THE AMES TEST AND THE COMET ASSAY
8 A NOTE ON THE USE OF TRADITIONAL MEDICINES IN OMAN, AND THE ANALYSIS OF THEIR HEAVY METAL CONTENT
9 A METHOD FOR THE SIMULTANEOUS IDENTIFICATION AND QUANTIFICATION OF FIVE SUPERWARFARIN RODENTICIDES IN HUMAN SERUM
10 STABILITY OF TRICYCUC DRUGS IN POST MORTEM BLOOD
11 SUPERCRITICAL FLUID EXTRACTION OF TEMAZEPAM FROM TOXICOLOGICAL SAMPLES
12 COMPARISON OF TECHNIQUES FOR ESTIMATION OF CARBOXYGHAEMOGLOBIN
13 DRUG SCREENING FOR DELIBERATE SELF-HARM PATIENTS PRESENTING TO THE EMERGENCY DEPARTMENT
14 EVALUATION OF IMMUNOLOGICAL SCREENING ASSAYS FOR BENZODIAZEPINES IN URINE USING CLINICAL SAMPLES
15 TRIAGE(tm) ANALYTICAL DEVICE FOR DRUGS OF ABUSE TESTING
16 MULTICENTER EVALUATION OF SIX CEDIA ASSAYS FOR DRUGS OF ABUSE SCREENING IN URINE
17 LEVOMETHADONE LEVELS IN SALIVA AND PLASMA OF L-POLAMIDON®-SUBSTITUTED PATIENTS
18 URINE EXCRETION OF AMPHETAMINE
19 MORPHINE EXCRETION IN RELATION TO CYP2D6 AFTER INGESTION OF CODEINE AND ETHYLMORPHINE
20 DETECTION OF METHADONE INTAKE BY IMMUNO-ANALYSIS OF URINE AFTER CHANGING FROM L-METHADONE TO D/I-METHADONE DURING METHADONE-MAINTENANCE THERAPY
21 URINARY EDDP (METHADONE METABOLITE) AS A MARKER OF COMPLIANCE AND DIVERSION OF METHADONE
22 PERFORMANCE OF ABUSCREEN® ONLINE(tm) IMMUNOASSAYS FOR THE DETECTION OF DRUGS OF ABUSE ON THE COBAS INTEGRA®
23 ON-BOARD REAGENT AND CALIBRATION CURVE STABILITY FOR THERAPEUTIC AND ABUSED DRUG TESTS ON THE COBAS® INTEGRA
24 ABUSED DRUG AND TOXICOLOGY MONITORING ON THE AXSYM® RANDOM ACCESS IMMUNOASSAY ANALYZER
25 APPLICATION OF THIN-LAYER CHROMATOGRAPHY FOR IDENTIFICATION OF BENZODIAZEPINES IN BIOLOGICAL FLUIDS
26 QUANTIFYING OF DRUG SCREENING WITH ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE (EMIT) IN URINE AT DU PONT AXA SX IMPROVES ROUTINE DIAGNOSIS
27 QUANTIFYING OF AMPHETAMINES, BENZODIAZEPINES, BARBITURATES, AND COCAINE WITH ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE (EMIT) IMPROVES ROUTINE DIAGNOSIS IN URINE
28 EFFECTS OF FLUOXETINE ON SERUM mCPP CONCENTRATION IN DEPRESSED PATIENTS
29 “DRUGS-and-DRIVING” PROBLEMS IN PRACTICE OF THE INSTITUTE OF FORENSIC RESEARCH IN CRACOW
30 TDM OF PERPHENAZINE ADMINISTERED AS A DEPOT FORMULATION
31 COMPARATIVE TOXICITIES OF TWO AMIKACIN DOSING REGIMENS IN CHILDREN
32 Comparison of FPIA vs CEDIA method for determination of Digitoxin, Theophyllin and Phenytoin
33 RPHPLC METHOD FOR MONITORING ROUTINLY CONCENTRATION OF CARBAMAZEPINE, PHENYTOIN, PHENOBARBITONE IN SERIN
34 A PHENOBARBITAL METHOD ON THE DIMENSION® CLINICAL CHEMISTRY SYSTEM
35 EFFECT OF BENZODIAZEPINES ON RAT ADRENOCORTICAL STEROIDOGENESIS
36 ASSESSMENT OF QUALITY OF OUTCOMES FROM THE OPERATION OF A TDM SERVICE
37 EVALUATION OF THE ABBOTT TDx® SERUM BENZODIAZEPINE IMMUNOASSAY FOR THE ANALYSIS OF LORAZEPAM, ADINAZOLAM AND N-DESMETHYLADINAZOLAM
38 IDENTIFICATION OF URINARY BENZODIAZEPINES USING
AUTOMATED MULTI-COLUMN LIQUID CHROMATOGRAPHY
39 A STEREOSELECTIVE HPLC METHOD FOR THE DETERMINATION OF METHADONE AND IS MAIN METABOLITE IN URINE (USING AN AGP COLUMN)
40 ANALYSIS OF FLUVOXAMINE, CLOBAZAM AND OTHER BENZODIAZEPINES ON THE SAME HPLC SYSTEM
41 SIMULTANEOUS DRUG MONITORING OF CITALOPRAM, CLOZAPINE, FLUOXETINE, MAPROTILINE, AND TRAZODONE IN SERUM BY HPLC ANALYSIS
42 HPLC/MS MEASUREMENT OF STEROID SULFATES AND GLUCURONATES
43 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF SOME ANTIARRHYTHMIC DRUGS USING CYANOPROPYL DERIVATIZED SILICA PHASE
45 IS A DIODE ARRAY DETECTOR REQUIRED FOR THE HPLC DETERMINATION OF WHOLE-BLOOD CYCLOSPORIN A?
46 ENANTIOSELECTIVE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE S(+) AND R(-) ENANTIOMERS Of OXCARBAZEPINE ME TABOLITES
47 N4-OCTADECYL-1-ß-D-ARABINOFURANOSYL-CYTOSINE
48 LIDOCAINE METABOLITE (MEGX) FORMATION CORRELATES WITH VINORELBIN CLEARANCE IN PATIENTS WITH METASTATIC BREAST CANCER
49 POPULATION PHARMACOKINETICS (PK) & PHARMACO DYNAMICS (PD) ANALYSIS AFTER A SINGLE INTRAVENOUS ADMINISTRATION OF FLECAINIDE ACETATE (FLC)
50 POPULATION PHARMACOKINETICS OF AMINOGLYCOSIDE ANTIBIOTICS IN PATIENTS WITH CYSTIC FIBROSIS
51 CYP2D6 PHENOTYPING BY AN AUTOMATED DETERMINATION OF DEXTROMETHORPHAN AND ITS MAIN METABOLITES IN HUMAN PLASMA
52 PHARMACOKINETIC PREDISPOSITION TO ENVIRONMENTAL TOBACCO SMOKE; A RISK FACTOR FOR PEDIATRIC ASTHMA
53 FACTITIOUS DISEASE BY PHENPROCOUMON ABUSE
54 CLINICAL PHARMACOKINETICS OF VERAPAMIL IN HEART TRANSPLANT PATIENTS UNDER CYCLOSPORINE BASED IMMUNOSUPPRESSION
55 TRANSPLACENTAL DIGOXIN PASSAGE IS INFLUENCED BY THE FETAL PERFUSION RATE IN THE ISOLATED PLACENTAL COTYLEDON
56 INHIBITORY EFFECTS OF FLUVOXAMINE ON THE METABOLISM OF CLOMIPRAMINE IN HUMAN AND RAT LIVER MICROSOMES
57 FK-506 BLOOD LEVELS IN PATIENTS WITH HEPATITIS C AFTER KIDNEY TRANSPLANTATION
58 INTERACTION OF TACROLIMUS (FK 506) AND FLUCONAZOLE
59 COMPARATIVE ANALYSIS OF TACROLIMUS IN WHOLE BLOOD BY PRO-TRAC(tm) ELISA AND MEIA IMX METHODS
60 WHOLE BLOOD FK-506 LEVELS IN RELATION WITH REJECTION OR NEPHROTOXICITY IN PATIENTS UNDERGOING LIVER TRANSPLANTATION
61 THERAPEUTIC DRUG MONITORING OF TACROLIMUS IN WHOLE BLOOD BY HPLC/MS/MS
62 COMPARISON BETWEEN WHOLE BLOOD TACROLIMUS BY ABBOTT IMx AND PLASMA TACROLIMUS BY ENZYME- LINKED IMMUNOASSAY
63 Comparison of different methods for the determination of cyclosporine-A in various groups of organ-transplantation patients
64 SEMI-AUTOMATED METHANOL EXTRACTION OF WHOLE BLOOD FOR CYCLOSPORIN ANALYSIS USING! THE SYVA EMIT METHOD
65 RPHPLC FOR MONITORING BLOOD CONCENTRATION OF CYCLOSPORINE A IN KIDNEY TRANSPLANTATION PATIENT AND CLINICAL APPLICATION
66 A MODIFIED HPLC METHOD FOR MEASURING CYCLOSPORINE A AND MONITORING ITS BLOOD CONCENTRATION
67 EFFECT OF METABOLIC INHIBITORS ON CYCLOSPORIN-A PHARMACOKINETICS STUDIED USING A POPULATION APPROACH
68 CLINICAL OUTCOME AND CYCLOSPORIN-A CONCENTRATION AFTER CARDIOTHORACIC TRANSPLANT
69 REDUCING THE COST OF CYCLOSPORIN ASSAYS
70 REPLACEMENT OF SERUM CYCLOSPORIN A ANALYSIS BY HPLC AND FPIA (POLYCLONAL) WITH A FPIA MONOCLONAL TECHNIQUE IN RENAL TRANSPLANT RECIPIENTS
71 REPLACEMENT OF HPLC AND FPIA (POLYCLONAL) WITH A FPIA (MONOCLONAL) TECHNIQUE FOR THE MEASUREMENT OF SERUM CYCLOSPORIN A POST CARDIAC AND LIVER TRANSPLANTATION
72 IMPROVED DETERMINATION OF CYCLOSPORINE AND ITS METABOLITES USING SOLID PHASE EXTRACTION DISKS AND NORMAL PHASE LIQUID CHROMATOGRAPHY
73 THERAPEUTIC OKT3 MONITORING BY FLOW CYTOMETRIC ASSAY IN KIDNEY TRANSPLANT RECIPIENTS
74 DETERMINATION OF RAPAMYCIN IN WHOLE BLOOD BY HPLC
75 THE BLOOD DISTRIBUTION AND SINGLE DOSE PHARMACO-KINETICS OF THE IMMUNOSUPPRESSANT LEFLUNOMIDE
76 MYCOPHENOLIC ACID BINDING TO PLASMA PROTEINS MODULATES ITS PHARMACOLOGIC ACTIVITY
77 DRUG MONITORING OF MIZORIBINE IN RENAL TRANSPLANT PATIENTS RECEIVING AN IMMUNOSUPPRESSIVE TRIPLE THERAPY
78 MONITORING OF HIGH DOSE METHOTREXATE THERAPY IN CHILDHOOD OSTEOGENIC SARCOM
79 PHARMACOKINETIC MONITORING OF HIGH DOSE METHOTREXATE IN ADULT AND CHILDHOOD OSTEOGENIC SARCOM
80 INTERMEDIATE DOSE METHOTREXATE TOXICITY
81 HIGH-DOSE METHOTREXATE TREATMENT IN CHILDREN WITH OSTEOGENIC SARCOMA
82 MONITORING PLATINUM CONCENTRATIONS IN SALIVA
83 INCREASE OF ADRIAMYCIN THERAPEUTIC EFFICACY THROUGH REDUCTION OF ANTHRACYCLINE TOXICITY BY CALCIUM GLUCONATE
84 PROBING METABOLIC INEFFICIENCY OF ORAL CYCLOPHOSPHAMIDE IN BREAST CANCER PATIENTS TREATED ACCORDING TO THE CMF-REGIMEN
85 DETERMINATION OF 2–CHLORO-2 '-DEOXYADENOSINE IN HUMAN BLOOD SERUM BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
86 Interference by Carbamazepine 10,11–Epoxide in Measurements or Carbamazepine by Immunoassay
87 A PROSPECTIVE RANDOMIZED CONTROLLED STUDY ON THE IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) IN PATIENTS WITH EPILEPSY
88 TDM OF AHTIEPILEPTICS DURING AND AFTER PREGNANCY
89 FREE AND TOTAL STEADY-STATE SERUM CONCENTRATIONS OF TRICYCLIC ANTIDEPRESSANTS
90 THERAPEUTIC BLOOD LEVELS OF TRICYCLIC ANTIDEPRESSANTS (TCA) ESTIMATED BY ENZYME MULTIPLIED IMMUNO ASSAY (EMIT) OR BY HPLC
91 IMPORTANCE OF MEASURING THE METABOLITE OF DISOPYRAMIDE IN PATIENTS WITH RENAL FAILURE
92 QUINIDINE IMMUNOASSAY SPECIFICITY
93 SPECIFITY OF FIVE DIGOXIN IMMUNOASSAYS TOWARDS β-METHYLDIGOXIN, DIGITOXIN, DIGOXIN METABOLITES, AND ALDOSTERONE ANTAGONISTS
94 HPLC method for Digoxin determination in blood serum or plasma
95 A BLOCKER REAGENT TO REDUCE DIGIBIND INTERFERENCE IN A NON-PRETREATMENT DIGOXIN ASSAY
96 PERFORMANCE COMPARISON OF THE ROCHE-TDM ONLINE(tm) ASSAY FOR DIGOXIN ON THE COBAS® MIRA. FARA AND INTEGRA INSTRUMENTS
97 DEVELOPMEMT OF TWO DIGOXIN ASSAYS FOR THE AxSYM® IMMUNOASSAY ANALYZER
98 MULTICENTER EVALUATION OF AN IMMUNO- TURBIDIMETRIC ASSAY FOR DIGOXIN
99 EVALUATION OF EMIT 2000® DIGOXIN ASSAY IN TWO AUSTRALIAN CENTRES - EMPHASIS ON DIGOXIN-LIKE IMMUNOREACTIVE SUBSTANCES
100 ROUTINE DETERMINATION OF SERUM PRIMIDONE LEVELS WITH A FULLY AUTOMATED LIQUID CHROMATOGRAPHIC METHOD
101 A NOVEL PLASMA EXTRACTION PROCEDURE FOR THE DETERMINATION OF THE ENANTIOMERS OF ETHOSUXIMIDE
102 SIMPLE HPLC METHOD FOR DETERMINATION OF ANTIEPILEPTIC DRUGS IN PLASMA
103 ROUTINE METHOD FOR THE DETERMINATION OF SERUM PHENYTOIN USING THE LIQUID CHROMATOGRAPHIC ALCA(tm) -SYSTEM
104 MULTICENTER EVALUATION OF THE CEDIA® IMMUNOASSAYS FOR CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL AND VALPROIC ACID ON HITACHI 704, 717 AND 911 ANALYZERS
105 IMMUNOASSAY FOR PHENYTOIN ON THE CIBA CORNING ACS
106 APPLICATION OF THE NEW MONOCLONAL COBAS®-FP PHENYTOIN AND VALPROIC ACID REAGENTS FOR THE ANALYSIS OF FREE PHENYTOIN AND FREE VALPROIC ACID ON THE COBAS INTEGRA® AND THE COBAS FARA II®
107 SIMPLIFIED AND RAPID HPLC PROCEDURE FOR ANALYSIS OF LAMOTRIGINE IN PLASMA
108 DETERMINATION OF BENTAZEPAM IN SERUM BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
109 ANALYSIS OF THE 7–AMINO METABOLITES OF FLUNITRAZEPAM, NITRAZEPAM AND CLONAZEPAM IN URINE
110 AUTOMATED DETERMINATION OF CLOZAPINE, N-DESMETHYLCLOZAPINE AND CLOZAPINE N-OXIDE BY COLUMN SWITCHING AND ON-LINE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
111 HPLC DETERMINATION OF E AND Z DOXEPIN AND E AND Z DESMETHYL-DOXEPIN
112 DETERMINATION OF VANCOMYCIN IN HUMAN SERUM BY CAPILLARY ISOTACHOPHORESIS
113 ENZYME IMMUNOASSAY AND RADIOIMMUNOASSAY SERUM MONITORING OF AMINOGLYCOSIDE ANTIBIOTICS; AMIKACIN AND DIBEKACIN
114 LATEX IMMUNOASSAYS FOR GENTAMICIN, TOBRAMYCIN, AND VANCOMYCIN ON THE DUPONT DIMENSION ANALYZER
115 DEVELOPMENT OF A SPECIFIC IMMUNOASSAY FOR VANCOMYCIN
116 DEVELOPMENT OF A CHEMILUMINESCENT IMMUNOASSAY FOR GENTAMICIN
117 EVALUATION OF TDM ASSAYS FOR ANTIBIOTICS ON THE COBAS® INTEGRA AND FARA II*
118 DETERMINATION OF THE ANTIMYCOTIC DRUG FLUCONAZOLE IN HUMAN PLASMA BY MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY
119 MICROCOLUMN HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC ASSAY FOR SALICYLIC ACID IN ISOLATED PULMONARY MACROPHAGES
120 QUANTITATION OF SALICYLATE BY THREE HOMOGENEOUS ASSAYS AND HPLC
121 Method for The Determination of Buphrenorphine in Serum by Gas-Chromatography-Mass-Spectrometry Using Single Ion Monitoring
122 METHOD WITH AN AUTOMATED CHEMILUMINESCENT IMMUNOASSAY
123 COMPARISON OF TECHNIQUES FOR ASSAY OF ETHANOL
124 HPLC METHOD FOR ANALYSIS A SMALL AMOUNT OF TROXERUTINE IN HUMAN PLASMA
125 AUTOMATED CAPILLARY ELECTROPHORESIS OF OMOCYSTINE IN URINE AND GLUTATHION IN RED BLOOD CELLS WITH SPECTROPHOTOMETRIC DETECTION
126 ENANTIOSELECTIVE QUANTITATION OF (R)- AND (S)- ALPRENOLOL BY GC/MS IN SALIVA AND PLASMA
127 EXTERNAL QUALITY ASSESSMENT SCHEME FOR CYCLOSPORIN MEASUREMENTS
128 ANALYSIS AND DOSING OF ANTIBIOTICS IN A RENAL PATIENT
129 PHARMACOKINETICS OF CYCLOSPORIN IN HEART TRANSPLANT PATIENTS AFTER ADMINISTRATION OF SANDIMMUN® AND A NEW ORAL FORMULATION -NEORAL®
130 SURGERY INDUCED CHANGES IN THE PHARMACOKINETICS OF ORAL CYCLOSPORIN IN A NEW GALENICAL FORMULATION IN KIDNEY TRANSPLANTED PATIENTS.-
131 IMPROVED EMIT ASSAY FOR SEMIAUTOMATED CYCLOSPORINE DETERMINATION
132 NEPHROTOXICITY UNDER IMMUNOSUPPRESSIVE THERAPY WITH CICLOSPRORINE A
133 PHARMACOKINETICS OF TACROLIMUS (TAC) IN TRANSPLANT PATIENTS
134 TACROLIMUS (FK506) KINETICS IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS
135 TACROLIMUS (FK-506; TAC) NEPHROTOXICITY AND ITS PREVENTION
136 TACROLIMUS (FK506) METABOLITE PATTERNS IN BLOOD FROM LIVER AND KIDNEY TRANSPLANT PATIENTS
137 VALIDATION OF PHARMACODYNAMIC MONITORING OF MYCOPHENOLIC ACID
138 RAPAMYCIN AND CYCLOSPORINE DRUG STUDIES IN THE RAT MODEL
139 ANALYSIS OF DRUGS OF ABUSE IN MECONIUM
140 CONFIRMATION OF GESTATIONAL COCAINE EXPOSURE BY NEONATAL HAIR ANALYSIS
141 MEASUREMENT OF DRUGS OF ABUSE ON THE DIMENSION® CLINICAL CHEMISTRY SYSTEM
142 QUANTITATIVE URINALYSIS IN HUMANS SMOKING MARIJUANA DAILY
143 COMPARATIVE PERFORMANCE OF FIVE UNIT TEST DEVICES FOR DRUGS OF ABUSE TESTING WITH SYVA EMIT(tm)
144 DIGOXIN-SPECIFIC FAB FRAGMENTS IN THE TREATMENT OF OLEANDER POISONING IN MAN
145 DETERMINATION OF FLUMAZENIL, A BENZODIAZEPINE ANTAGONIST, IN SERA OF BENZODIAZEPINE-OVERDOSED PATIENTS
146 RELATIONSHIP BETWEEN METHADONE DOSE, HAIR METHADONE CONCENTRATION AND HAIR COLOUR IN MAN
147 EXPOSURE TO ENVIRONMENTAL HAZARDS RELATED TO AGE, GENDER AND MICRONUCLEI
148 FIELD INVESTIGATION OF AN AUTHORIZED TEMPORARY PESTICIDE RESIDUES WASTE SITE
149 GENOTYPING OF N-ACETYLTRANSFERASE POLYMORPHISM AND ITS APPLICATION TO PROCAINAMIDE TDM
150 THE ROLE OF CYP2D6 AND CYP2C19 IN THE STEREOSELECTIVE METABOLISM OF THIORIDAZINE IN PATIENTS
151 THE ASSOCIATION OF SLOW ACETYLATOR PHENOTYPE WITH THE OCCURRENCE OF CONVULSIONS IN CHILDREN
152 INTERACTION BETWEEN CLOMIPRAMINE AND FLUOXETINE IN MAYOR DEPRESSIONS
153 THERAPEUTIC MONITORING OF TRICYCLIC ANTIDEPRESSANTS AND PHARMACO-EEG
154 MIDAZOLAM
155 CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE. STUDIES WITH CONVENTIONAL AND SLOW-RELEASE PREPARATIONS IN CHILDREN AND ADOLESCENTS WITH EPILEPSY
156 CHANGES OF TOTAL AND FREE CARBAMAZEPINE LEVELS
157 INTERACTIONS OF OTHER ANTIEPILEPTIC DRUGS WITH CLONAZEPAM AND RELATED MECHANISM
158 A PHARMACOKINETIC STUDY OF PACLITAXEL IN PATIENTS WITH METASTATIC COLORECTAL CANCER
159 EVALUATION OF RELATIVE BIOAVAILABILITY OF TWO STOBADINE PREPARATIONS IN DOGS
160 COMPARATIVE PHARMACOKINETICS OF THEOPHYLLINE IN RAEBITS AND IN HUMANS WITH HYPERLIPIDEHIA
161 ROCHE TDM AND THYROID ASSAYS ON THE COBAS® INTEGRA
162 URINE PHARMACOKINETICS OF CODEINE IN HEALTHY VOLUNTEERS
163 A NEW APPROACH TO TREATMENT OF ONCOLOGICAL PATIENTS WITH CONCOMITANT TOXIC LIVER DISORDERS
164 PHARMACOKINETICS OF I.V. THEOPHYLLINE (theo) IN ASTHMATIC CHILDREN
165 POPULATION PHARMACOKINETICS OF TOBRAMYCIN
166 DEVELOPMENT OF GENTAMICIN POPULATION MODELS FOR ICU AND NON-ICU PATIENTS USING A NON PARAMETRIC ALGORITHM (NPEM)
167 A COMPUTER PROGRAM WITH GUI FOR CALCULATING DISTRIBUTION OF DRUGS IN DISEASED STATE BASED ON PHYSIOLOGICAL PHARMACOKINETIC MODEL
168 AMINOGLYCOSIDES DOSING NOMOGRAM FOR NEONATES, CHILDREN, AND ADULTS
169 CORRELATION BETWEEN CREATININE CLEARANCE AND ELIMINATION CONSTANT OF TOBRAMYCIN IN ADULT PATIENTS WITH CYSTIC FIBROSIS
170 EVALUATION OF INDIVIDUALIZED ISEPAHICIN DOSING REGIMENS
171 ASSESSMENT OF COMPUTER PROGRAMS FOR ANTIBIOTICS DOSING REGIMENS
172 PHARMACOKINETIC-PHARMACODYNAMIC MODEL OF PROPRANOLOL AND ITS METABOLITE 4–HYDROXYPROPRANOLOL
173 PHARMACOKINETIC-DYNAMIC CORRELATION OF CIBEZOLINE IN RATS
174 LITHIUM OVERDOSE
175 LIQUID CHROMATOGRAPHIC DETERMINATION OF IOHEXOL AND PAH WITH CHROMOSORB P COLUMN USED FOR SAMPLE PREPARATION
176 DETERMINATION OF RENAL TUBULAR SECRETION BY KINETIC METHODS APPLYING P-AMINO-HIPPURIC ACID
177 A TABLE FOR QUICK ESTIMATION OF CREATTNINE CLEARANCE
178 MEGX TEST AND MAYO CLINIC PROGNOSTIC SCORE IN PRIMARY BILIARY CIRRHOSIS (PBC)
179 THE MEGX TEST IN THE SELECTION OF LIVER TRANSPLANT DONORS
180 LIVER FUNCTION AFTER TRANS-ARTERIAL OILY CHEMOEMBOLIZATION (TOCE) FOR HEPATOCELLULAR CARCINOMA
181 DOES HIGH-FLOW ASCITES COMPROMISE THE MEGX-TEST?
182 MONOETHYLGLYCINEXYLIDIDE (MEGX) FORMATION CAN COMPLETE CLINICAL STAGING OF CIRRHOSIS
183 INTERRELATIONSHIPS BETWEEN LIDOCAINE ELIMINATION AND MONOETHYLGLYCINEXYLIDIDE FORMATION IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS OR CIRRHOSIS
184 VALUE OF LIDOCAINE METABOLITE FORMATION AS HEPATIC FUNCTION TEST IN PATIENTS WITH CHRONIC LIVER DISEASES
185 AZATHIOPRINE PHARMACOGENETICS
186 AZATHIOPRINE THERAPY IN RENAL ALLOGRAFT RECIPIENTS
187 CICLOSPORIN METABOLITE PATTERNS AND IMPAIRED KIDNEY FUNCTION IN LIVER GRAFT RECIPIENTS
188 UTILITY OF FLUORESCENCE POLARIZATION IMMUNOASSAY FOR ANALYSIS OF CYCLOSPORINE IN ANIMAL TISSUES
189 CYCLOSPORIN TROUGH LEVELS CORRELATE WITH SERUM LIPOPROTEINS AND APOLIPOPROTEINS IN RENAL TRANSPLANT RECIPIENTS
190 EVALUATION OF THE NEW PRO-TRACR TACROLIMUS MONOCLONAL WHOLE BLOOD ELISA FOR MONITORING OF TACROLIMUS LEVELS IN PATIENTS AFTER KIDNEY, HEART AND LIVER TRANSPLANT
191 DEVELOPMENT OF A SPECIFIC ASSAY TO DETERMINE TACROLIMUS WHOLE BLOOD LEVELS IN HEPATIC AND RENAL TRANSPLANT PATIENTS
192 SENSITIVE AND SPECIFIC QUANTIFICATION OF SIROLIMUS (RAPAMYCIN) AND ITS METABOLITES IN BLOOD AND URINE OF KIDNEY GRAFT RECIPIENTS USING HPLC/ELECTRO-SPRAY-MASS SPECTROMETRY (LC/ES/MS)
193 FEASIBILITY OF AN EMIT® ASSAY FOR MYCOPHENOLIC ACID IN PLASMA
194 MONITORING STEROID WITHDRAWAL BY IMMUNOCOMPETENCE ASSAY
195 THERAPEUTIC DRUG MONITORING USING QUANTITATIVE URINE MONITORING
196 IMPACT OF TDM OF ANTIBIOTICS ON CLINICAL OUTCOME
197 ONCE DAILY NETILMICIN INDIVIDUALIZED DOSED IN PATIENTS WITH NOSOCOMIAL PNEUMONIA
198 A VANCOMYCIN DOSING NOMOGRAM FOR NEONATES, INFANTS, CHILDREN, AND ADULTS
199 THERAPEUTIC DRUG MONITORING IN THE ELDERLY
200 CONCENTRATION CONTROLLED TRIALS - THE NEED 200 FOR PRE-TRIAL ASSAY VALIDATION
201 FELBAMATE MONITORING BY REVERSED-PHASE AND AUTOMATED PRESTATION(tm) LIQUID CHROMATO-GRAPHY. Wong SHY
202 PHARMACOKINETICS OF BIPERIDEN AS STUDIED WITH 202 AN AUTOMATIC HPLC/GC-MS METHOD
203 Creatinine deiminase (EC 3.5.4.21) from bacterium BN11
204 ESTIMATION OF RENAL FUNCTION USING RANDOM, SPOT 204 URINE COLLECTIONS
205 GENTAMICIN DOSING IN SOUTH AFRICAN NEONATES
Announcement
Erratum